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with MCV (16.7% vs 38.6% vs 26.3%; p¼0.042), mainly due to a higher
need for permanent pacemakers (6.3% vs 24.6% vs 10.5%; p¼0.019).
After multivariate analysis MCV remained predictor of VARC com-
bined early safety endpoints.General
n[162ACCURATE
n[48CoreValve
n[57SAPIEN XT
n[57 pAge (y) 82.636.55 82.295.33 82.397.72 83.146.32 0.75
Male (n) 45.7% (74) 45.8% (22) 45.6% (26) 45.6% (26) 1BMI (Kg/m2) 26.964.33 28.393.93 25.604.13 27.114.49 0.001
Hypertension (n) 83.1% (133) 85.4% (41) 76.8% (43) 87.5% (49) 0.28Diabetes (n) 34.4% (55) 33.3% (16) 32.1% (18) 37.5% (21) 0.823COPD (n) 11.9% (19) 21.3% (10) 7.1% (4) 8.9% (5) 0.073Coronary Artery
Disease > 50% (n)51.9% (83) 47.9% (23) 53.6% (30) 53.6% (30) 0.806Creattinine
Clearance < 60mL/
min (n)71.7% (114) 68.8% (33) 81.8% (45) 64.3% (36) 0.105NYHA Functional Class
III/IV (n)74.7% (118) 89.6% (43) 69.6% (39) 66.7% (36) 0.016EUROSCORE II 7.596.42 6.534.5 8.296.66 7.857.49 0.41
STS PROM 6.033.7 6.072.81 5.453.08 6.634.82 0.441
Left Ventricle Ejection
Fraction (%)57.4113.15 58.6610.79 57.0214.4 56.7213.8 0.998Mean Aortic Valve
Gradient (mmHg)52.8414.92 50.9113.01 53.2615.90 54.0415.50 0.575Aortic Valve Area
(cm2)0.690.15 0.730.16 0.670.14 0.670.14 0.105CONCLUSIONS Although the three devices have shown good device
success rates and hemodynamic improvement on echocardiogram,
CoreValve use lead to higher combined early safety endpoints, mainly
because of more permanent pacemaker usage. Larger cohorts or ran-
domized trials are needed do corroborate these ﬁndings.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS TAVI, TAVR, Transfemoral aortic valve replacement
TCT-629
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BACKGROUND Increased aortic valve calciﬁcation has been shown to
be associated with perivalvular regurgitation (PVR) post TAVR.
Nonetheless, there is limited data on the impact of extremely low
aortic valve calciﬁcation on the acute success of balloon-expandable
TAVR.
METHODS We studied patients with severe aortic stenosis that un-
derwent balloon-expandable TAVR and had a pre-procedural non-
contrast CT. Patients that had an aortic valve calciﬁcation score
(AVCS) of less than 1500 Agatston units (AU) were compared to pa-
tients with higher calciﬁcation scores.
RESULTS Seventy-four patients had low AVCS compared to 489 with
higher AVCS (mean Agatston score: 1049305 vs. 39892020). Pa-
tients with mild aortic valve calciﬁcation were younger (80.38 vs.
82.98.1; p¼0.01), had higher body mass index (29.17.4 vs. 26.85.8;
p¼0.01) and had female predominance (70.3% vs. 32.1%; p<0.001),
compared to patients with higher calciﬁcation scores. Pre-TAVR, pa-
tients with aortic valve calciﬁcation score 1500 had lower mean
aortic valve pressure gradient and less stenotic aortic valves
(37.39.8mmHg vs. 46.813.4mmHG; p<0.001 and 0.670.13cm2 vs.
0.630.15cm2; p¼0.02). Device success was 100% in the low calciﬁ-
cation group compared to 95.9% in patients with higher AVCS
(p¼0.076). Postdilatation and 2nd valve implantation was done in
8.8% and 0% compared to 9.5% and 3.7%, respectively (p¼0.85 and
0.09). Postprocedural PVR in the mild aortic valve calciﬁcation group
was lower (mild or more PVR: 13.5% vs. 25.9%; p¼0.023).There was nocase of valve embolization in the mild AVCS group. Thirty-day mor-
tality and major complications were similar between groups (Table).
One year mortality was 13.2% vs. 16.4% in the AVCS1500 vs.
AVCS>1500, respectively (p¼0.61).
Table. Procedural details and 30-days clinical outcomeAVCS £ 1500 Agatston
units
(n[74)AVCS > 1500 Agatston
units
(n[489) p-valueProcedural details:Device success 74 (100) 469 (95.9) 0.072nd valve 0 (0) 18 (3.7) 0.09Postdilatation 7 (9.5) 43 (8.8) 0.85Perivalvular leak: 0.02None / trace 64 (86.5) 358 (74.1)Mild 10 (13.5) 111 (23)Moderate 0 (0) 13 (2.7)Severe 0 (0) 1 (0.2)Valve embolization 0 (0) 3 (0.6) 0.530-days outcome:Mortality 1 (1.4) 13 (2.1) 0.5CVA/TIA 1 (1.4) 14 (2.9) 0.45Major bleeding 3 (4.1) 19 (3.9) 0.94Major vascular 4 (5.4) 13 (2.7) 0.2New permanent
pacemaker3 (4.9) 40 (10.1) 0.2Values are n (%).
CONCLUSIONS Balloon-expandable TAVR can be performed safely in
patients with extremely low AVCS. We demonstrated excellent acute
procedural outcome, lower rates of postprocedural PVR and no case of
valve embolization.
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BACKGROUND In patients with severe aortic stenosis undergoing
transfemoral aortic valve implantation (TAVI) device success was
signiﬁcantly higher with the balloon-expandable Edwards XT valve
(EXT) compared with the self-expanding CoreValve (CV) in the ran-
domized CHOICE trial. The second generation Edwards Sapien 3 valve
was designed to reduce paravalvular aortic regurgitation. Absence of
post-procedural aortic regurgitation was associated with a lower acute
and long-term mortality in the Partner trial. We compared the
outcome of the ES3 with the CoreValve in patients undergoing TAVI.
METHODS The ﬁrst 100 consecutive patients treated with the ES3
were compared with the last 100 consecutive patients treated with the
CoreValve (Clinical Trial Registration: NCT02162069). Mean STS-Score
was 10.27.9%. Post-procedural aortic regurgitation, rate of perma-
nent pacemaker implantation, and device success were analyzed ac-
cording to VARC criteria. Device size was based on multislice
computer tomography performed with a 256 Philips Brilliance iCT
scanner. Measurements of aortic annulus, left ventricular outﬂow
tract (LVOT) were performed with a dedicated software (3mensio
Structural Heart, version 7.0).
RESULTS Baseline characteristics were mostly similar between the
CoreValve and ES3 population: age 816 vs. 826 years (p¼0.24),
female 49% vs. 52% (p¼0.67), diabetes mellitus 34% vs. 38% (p¼0.56),
coronary artery disease 61% vs. 60% (p¼0.89), history of cardiac
surgery 14% vs. 9% (p¼0.27), pulmonary disease 36% vs. 60%
(p<0.01). Also the computer tomography acquired parameters did not
differ signiﬁcantly between the EXT and ES3 population. Post dilation
was necessary in 11% after CoreValve implantation and in no patient
after ES3 implantation (p<0.01). Rate of device success according to
B258 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5VARC was signiﬁcantly higher in the ES3 population with 93% vs. 76%
in the CV group (p<0.01). There was no annulus rupture, coronary
obstruction or periprocedural death. The rate of postprocedural non-
disabling or disabling stroke was similar. There was a statistical sig-
niﬁcance in the rate of paravalvular aortic regurgitation by
postprocedural echocardiography with moderate or severe aortic
regurgitation of 20% in the CV population versus 1% in the ES3 pop-
ulation (p<0.01). Numbers for mild regurgitation were 43 % vs. 31 %
(p¼0.22), none or trace 37% vs. 68% (p<0.01), respectively. Life
threatening bleeding according to VARC was similar (CV 1% vs. ES3
0%, p¼0.37). There was a statistical signiﬁcant lower rate of post-
procedural new pacemaker implantation for the ES3 with 15% versus
31% for the CV (p<0.01).
CONCLUSIONS Transfemoral TAVI with the new ES3 compared with
the CoreValve was associated with a statistical signiﬁcant lower rate of
moderate or severe aortic regurgitation, signiﬁcant lower need for
pacemaker implantation and a signiﬁcant higher rate of device suc-
cess according to VARC.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS Aortic stenosis, TAVI
TCT-631
Comparison of the second generation Edwards Sapien 3 valve with the
Edwards Sapien XT for transfemoral aortic valve implantation (TAVI)
Julia Seeger,1 Birgid Gonska,1 Christoph Rodewald,1 Sinisa Marcovic,1
Dominik Scharnbeck,1 Wolfgang Rottbauer,1 Jochen Wöhrle1
1University of Ulm, Ulm, Germany
BACKGROUND Moderate and severe aortic regurgitation after TAVI
with the Edwards Sapien XT (EXT) valve were associated with a higher
acute and long-term mortality in the Partner trial. The second gen-
eration Edwards Sapien S3 (ES3) valve has an outer skirt at the distal
part of the valve, designed to reduce paravalvular aortic regurgitation.
We compared outcome of patients after TAVI with the EXT and ES3 in
200 patients.
METHODS The ﬁrst 100 consecutive patients treated with the ES3
were compared with the last 100 consecutive patients treated with the
EXT valve (Clinical Trial Registration: NCT02162069). Mean STS-Score
was 118%. Postprocedural paravalvular regurgitation, rate of pace-
maker implantation and device success were analyzed according to
VARC criteria. Sizing was based on multislice computer tomography
performed with a 256 Philips Brilliance iCT scanner. Measurements of
aortic annulus, left ventricular outﬂow tract (LVOT) and distance from
annulus to coronary ostia were measured with a dedicated software
(3mensio Structural Heart,version 7.0).
RESULTS Baseline characteristics were similar between the EXT and
ES3 population Also the following computer tomography acquired
parameters did not differ signiﬁcantly between the EXT and ES3
population: aortic annulus area derived diameter 24.42.3 vs.
24.72.4 mm (p¼0.37), aortic annulus perimeter derived diameter
25.72.4 vs. 25.42.5 mm (p¼0.45), aortic annulus area 46799 vs.
48396 mm2 (p¼0.25), LVOT area derived diameter 24.32.8 vs.
24.62.6 mm (p¼0.48), LVOT perimeter derived diameter 25.52.9 vs.
25.62.6 mm (p¼0.94), LVOT area 471108 vs. 480101 mm2
(p¼0.52), heavy calciﬁcation of the aortic annulus (Rosenhek Grade
IV) 94% vs. 100% (p¼0.67) or heavy calciﬁcation of the LVOT 32% vs.
33% (p¼0.88). Size of the EXT was 23mm in 31%, 26mm in 44%, 29mm
in 25%. Numbers for ES3 were 29%, 50% and 21%, respectively. Post
dilation was done in 1% after EXT implantation and none after ES3
implantation. Rate of device success according to VARC was high in
both groups (p¼0.77). There was one intraprocedural death in the EXT
group, none in the ES3 population. There was no annulus rupture or
coronary obstruction. The rate of postprocedural stroke was similar
(p¼0.52). There was a higher rate of mild to severe aortic regurgitation
in postprocedural echocardiography of 42% in the EXT population
versus 32% in the ES3 group (p¼0.12). No severe aortic regurgitation
was found in neither group. Life threatening bleeding according to
VARC was signiﬁcantly lower with ES3 versus EXT (0% vs. 9%,
p<0.01). The need for permanent pacemaker implantation was higher
for EXT with 22% versus 15% for ES3 (p¼0.20).
CONCLUSIONS Transfemoral TAVI with the second generation ES3
compared with the EXT resulted in a lower rate of aortic regurgitation
(mild-severe), lower need for pacemaker implantation and a signiﬁ-
cantly lower bleeding risk.
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BACKGROUND Transfemoral transcatheter aortic valve replacement
(TF TAVR) can be performed under general anesthesia (GA) or mod-
erate sedation (MS). Despite observational studies suggesting a
shorter length of stay (LOS), shorter procedural time and a similar
mortality rate with MS, only 5% of patients undergoing TF TAVR in
the United States are done with this type of anesthesia. We reviewed
the implementation of a MS for TF TAVR protocol at a single institu-
tion with no previous experience with this technique.
METHODS Patients with severe obstructive sleep apnea (OSA), likely
difﬁcult intubation, inability to tolerate supine position due to
musculoskeletal disease, or barriers to communication including
altered mental status were performed under GA with intraoperative
transesophageal echocardiography. All others received MS with an
ilioinguinal nerve block and intraoperative transthoracic echocardi-
ography. The MS for TF TAVR protocol was implemented on October
9th, 2014. The records of patients undergoing TF TAVR 6 months
before and after protocol implementation were retrospectively
reviewed.
RESULTS In the pre protocol group 33 patients underwent TF TAVR
under GA and no patients received MS. In the post protocol group, 97
underwent TF TAVR, 81 (83.5%) of which received MS. OSA was the
most common reason for GA (N¼10, 62.5%). Conversion from MS to GA
occurred in 2 cases (2.5%) due to procedural complications, of which 1
resulted in death. All other cases involving MS were tolerated well and
there were no anesthesia related complications. Post procedural LOS
(3.2 days vs. 5.0 days, p¼0.002) and procedure time (144.0 minutes vs.
96.1 minutes, p<0.001) were both signiﬁcantly shorter in post proto-
col group. The post protocol group was also signiﬁcantly less likely to
require a skilled nursing facility upon discharge (24.2% vs. 8.2%,
p¼0.027). In hospital mortality was similar between groups (N¼2 6.1%
vs. N¼3, 3.1%, p¼0.601).Pre-Protocol Post-Protocol p-ValueN 33 97Moderate Sedation: N
(%)0 (0) 81 (83.5)Post Procedure Length
of Stay: Days5.0  3.2 (4) 3.2 2.8 (3) 0.002Procedure Time:
Minutes144.0  54.9 (129) 96.1  31.3 (88) <0.001Skilled Nursing Facility
on Discharge: N (%)8 (24.2) 8 (8.2) 0.027In Hospital Mortality:
N (%)2 (6.1) 3 (3.1) 0.601NOTE: Values are in numbers, means  SD (medians), or numbers (percentages).
CONCLUSIONS The MS for TF TAVR protocol appears safe and can be
rapidly implemented at institutions with no previous MS experience.
This technique is feasible in the majority of patient undergoing TF
TAVR. Post procedural LOS and procedural time are multifactorial, but
this data further suggests MS may be beneﬁcial in select patients.
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